An interventional study of DTRAX Graft in Cervical Spondylosis, Cervical Radiculopathy and Cervical Degenerative Disc Disease, sponsored by Providence Medical Technology, Inc.. Withdrawn at 2 sites in United States. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by Providence Medical Technology, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Spondylosis with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Spondylosis · United States.
Among the 63 studies in Spondylosis with a site in United States, this one is the 42nd largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2012, is one of 34 with no phase, and was the 8th registered.
142 studies on the registry are indexed under Spondylosis; 41 are open to participants now.
Browse Spondylosis studies →17 of the 63 studies in Spondylosis with a site in United States are open now. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 18+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
University of Arkansas · Sites in United States
Ages 18+
University of New Mexico · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Spondylosis studies recruiting now, 12 (44%) set no upper age limit and 10 (37%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 35 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 45 across the 45 interventional studies, 78 across the 18 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 63 have an industry lead sponsor. The 10 most frequent:
Providence Medical Technology, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Providence Medical Technology, Inc. has 1 study filed under Spondylosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Spondylosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04140344Duke UniversityThe NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions | 2026-12 |
| NCT06268704University of New MexicoParticulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection | 2027-01-01 |
| NCT05356286University of California, Los AngelesRecording of Intraoperative Spinal Cord Stimulation and Monitoring | 2027-01-22 |
| NCT05029726John O'TooleRegional Anesthesia in Minimally Invasive Lumbar Spine Surgery | 2027-02-01 |
| NCT06361485R3 Stem CellSafety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 63 studies in Spondylosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
DTRAX Graft is used to relieve nerve pressure in the neck in order to provide relief for Cervical Degenerative Disc Disease. This study is being conducted to determine the effectiveness of the graft, and to find out whether or not it provides better results or faster healing than traditional ways of performing surgery for Cervical Degenerative Disc Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject diagnosed with DDD in C3-C7, defined as follows:
Radiographically (at least one):
Clinically: radicular symptoms (at least one):
Subject has single-level disease, OR multi-level disease demonstrated radiographically, and confirmed to be symptomatic by one of the following methods:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: DTRAX Graft
DTRAX Graft is an allograft implant inserted to support spinal fusion.
Gather clinical outcome data on DTRAX Graft.
Clinical outcome data will be collected using the Neck Disability Index (NDI), Visual Analogue Scale (VAS), and a quality of life questionnaire.
Time frame: Baseline throughout 12 months post-operatively
Safety information will be evaluated by collecting the type, frequency, severity, device, and procedure-relatedness of adverse events.
Time frame: Baseline throughout 12 months post-operatively
Start is estimated for May 2012; primary completion for Feb 2014, 21 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Providence Medical Technology, Inc.